Drug intelligence / Profile preview

HH019

Development stage: Preclinical
Lead developer: Huahui Health
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HH019 is an investigational antibody-drug conjugate (ADC) being developed by Huahui Health for the treatment of solid tumors. As an ADC, it is designed to leverage the targeting specificity of a monoclonal antibody to deliver a potent cytotoxic payload directly to cancer cells, thereby enhancing therapeutic efficacy while potentially reducing systemic side effects. HH019 is part of Huahui Health's oncology pipeline, which focuses on advanced antibody formats including bispecific and trispecific modalities to address unmet needs in cancer therapy.

Beyond the preview

Go deeper on HH019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HH019.

Explore the full profile